Floor Plan of Conference Rooms

Masato Odawara, M.D., Ph.D.

Curriculum Vitae

Affiliation: The Department of Diabetes, Endocrinology, Metabolism and Rheumatology, Tokyo Medical University Position: Director and Professor Email: odawara@tokyo-med.ac.jp

Education/ Appointments

1980 Graduated School of Medicine and Faculty of Medicine, University of Tokyo. Medical Doctor 1999 Doctor of Philosophy(PhD), University of Tokyo 1990 Research Assistant, Tokyo University Hospital 1992 Lecturer, Institute of Clinical Medicine, University of Tsukuba 1996 Clinical Lecturer of Medicine, Oxford University 2000 Director, Division of Endocrinology and Metabolism, Department of Internal Medicine, Toranomon Hospital, Federation of National Public Service Personnel Mutual Aid Associations 2004 Director and Professor of the Third Department of Internal Medicine, Tokyo Medical University Visiting Professor, Tokyo University of Pharmacy and Life Sciences 2009.9-2012.8 Executive Vice President of Tokyo Medical University Hospital 2014.4- Director and Professor of the Department of Diabetes, Endocrinology, Metabolism and Rheumatology, Tokyo Medical University 2015 Executive Director of Japan Diabetes Foundation. Director of a board of Japan Society of Adult Diseases Director of a board of Japan Society of Diabetic Complications 2018.1 President of Japan Society of Adult Diseases

Research Interests

Research on genetic predisposition for the development of type 2 diabetes mellitus and diabetic microvascular and macrovascular complications.

Clinical trials on diabetic complications and treatment.

Brief List of Publications (Selected)

1. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, Haraguchi M, Morita A, Ohashi K,

Hara K, Morise A, Izumi K, Ishizuka N, Ohashi Y, Noda M, Kadowaki T; J-DOIT3 Study Group. :

Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017 Oct 24. pii: S2213-8587(17)30327-3. 2. Narisawa H, Komada Y, Miwa T, Shikuma J, Sakurai M, Odawara M, Inoue Y.: Prevalence, symptomatic features, and factors associated with sleep disturbance/insomnia in Japanese patients with type-2 diabetes. Neuropsychiatr Dis Treat. 2017 Jul 18;13:1873-1880. 3. Yamada H, Tanaka A, Kusunose K, Amano R, Matsuhisa M, Daida H, Ito M, Tsutsui H, Nanasato M,

Kamiya H, Bando YK, Odawara M, Yoshida H, Murohara T, Sata M, Node K; PROLOGUE Study

Investigators.: Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study. Cardiovasc

Diabetol. 2017 May 11;16(1):63. 4. Seki M, Kawai Y, Ishii C, Yamanaka T, Odawara M, Inazu M.: Functional analysis of choline transporters in rheumatoid arthritis synovial fibroblasts. Mod Rheumatol. 2017 Nov;27(6):995-1003.

5. Kozlovski P, Fonseca M, Mohan V, Lukashevich V, Odawara M, Paldánius PM, Kothny W.: Effect of race and ethnicity on vildagliptin efficacy: A pooled analysis of phase II and III studies. Diabetes Obes Metab. 2017 Mar;19(3):429-435. 6. Shikuma J, Kan K, Ito R, Hara K, Sakai H, Miwa T, Kanazawa A, Odawara M.: Critical review of

IgG4-related hypophysitis. Pituitary. 2017 Apr;20(2):282-291. 7. Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K,

Ohno J, Iida M, Sano H, Tomiyama H, Inoue T, Tanaka A, Murohara T, Node K; PROLOGUE Study

Investigators.: Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a subanalysis of the PROLOGUE study. Cardiovasc Diabetol. 2016 Sep 13;15(1):134. 8. Sakai H, Nagao H, Sakurai M, Okumura T, Nagai Y, Shikuma J, Ito R, Imazu T, Miwa T, Odawara

M. Correction: Correlation between Serum Levels of 3,3´,5´-Triiodothyronine and Thyroid

Hormones Measured by Liquid Chromatography-Tandem Mass Spectrometry and Immunoassay. PLoS One. 2016 Jul 7;11(7):e0159169. 9. Odawara M, Ishii H, Tajima N, Iwamoto Y.: Impact of patient attitudes and beliefs to insulin therapy upon initiation, and their attitudinal changes after initiation: the DAWN Japan study. Curr Med Res Opin. 2016;32(4):681-6. 10. Odawara M, Miyagawa J, Iwamoto N, Takita Y, Imaoka T, Takamura T.: Once-weekly glucagonlike peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52weeks of treatment in a randomized phase III study. Diabetes Obes Metab. 2016 Mar;18(3):249-57. 11. Hara K, Kadowaki T, Odawara M.: Genes associated with diabetes: potential for novel therapeutic targets? Expert Opin Ther Targets. 2016;20(3):255-67. 12. Sakai H, Nagao H, Sakurai M, Okumura T, Nagai Y, Shikuma J, Ito R, Imazu T, Miwa T, Odawara

M. Correlation between Serum Levels of 3,3’,5’-Triiodothyronine and Thyroid Hormones Measured by Liquid Chromatography-Tandem Mass Spectrometry and Immunoassay. PLoS One. 2015 Oct 1;10(10):e0138864. 13. Miyagawa JI, Odawara M, Takamura T, et al.: Once weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomised phase 3 study. Diabetes Obes Metab. 2015 14. Rakugi H, Ogihara T, Saruta T, .., Odawara M, et al.: COLM Investigators. Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis. J Hypertens. 2015 15. Odawara M, Yoshiki M, Sano M, Hamada I, Lukashevich V, Kothny W. Efficacy and safety of a single-pill combination of vildagliptin and metformin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled trial. Diabetes Ther. 2015 Mar;6(1):17-27. 16. Odawara M, Kadowaki T, Naito Y. Effectiveness and safety of basal supported oral therapy with insulin glargine, in Japanese insulinnaive, type 2 diabetes patients, with or without microvascular complications: subanalysis of the observational, non-interventional, 24-week follow-up Add-on Lantus® to Oral Hypoglycemic

Agents (ALOHA) study. J Diabetes Complications. 2015 17. Garg SK, Admane K, Freemantle N, Odawara M, et al.: Patient-led versus physician-led titration of insulin glargine in patients with uncontrolled type 2 diabetes: a randomized multinational atlas study. Endocr Pract. 2015.

Juliana Chan, MBChB, M.D., FHKAM,

FRCP

Professor Juliana Chan is Chair Professor of Medicine and Therapeutics and Director, Hong Kong Institute of Diabetes and Obesity and Director, Clinical Research Management Office, The Chinese University of Hong Kong, Prince of Wales Hospital. She graduated from the Liverpool University, UK and is a clinician scientist with accreditations in endocrinology and clinical pharmacology.

In 1995, she established the Hong Kong Diabetes Registry to characterize the clinical course and genetic associations of diabetes. In 2007, she established the Asia Diabetes Foundation and developed the web-based Joint Asia Diabetes Evaluation (JADE) Programme which demonstrated the benefits of using information technology and integrated care to improve clinical outcomes. The accompanying biobanks of these cohorts have also formed the basis of large scale projects to use multi-omic approaches to discover genetic causes of diabetes and its complications. She has trained more than 50 postgraduate students/fellows and co-authored 500 articles and 20 book chapters. She is a member of steering committees of international surveys and randomized outcome trials in diabetes and cardiovascular-renal disease. She is a recipient of the Peter Bennet Epidemiology Award and Asian Association for Study of Diabetes Epidemiology Award and is currently leading a Lancet Diabetes Commission to advocate the use of systems and policies to close the gaps in diabetes care, data and outcomes.